Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772693 · ClinicalTrials.gov registry record · NA
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01772693: Completed NA study, sponsored by InSightec.
NCT01772693 is a NA study that has completed, run by InSightec. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01772693, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial system compared to a Sham Vim thalamotomy procedure. Data will be collected to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy. The Sham treatment data will be used to evaluate placebo effect from treatment.
Primary Outcome
Evaluate of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor-dominant PD during the ExAblate treatment. Primary safety analyses are reported in the adverse events module.
Interventions
- DEVICE ExAblate Transcranial MRgFUS
- DEVICE Sham ExAblate Transcranial MRgFUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-09 |
| Est. Completion | 2019-03 |
| Phase | NA |
What the finished NCT01772693 record still lists
NCT01772693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which ExAblate Transcranial MRgFUS is the first listed.
NCT01772693 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01772693 about?
NCT01772693 is a clinical study titled "ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease". This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial system compared to a Sham Vim thalamotomy...
What is the current status of trial NCT01772693?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2012-09. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01772693?
The interventions under investigation include: ExAblate Transcranial MRgFUS (DEVICE), Sham ExAblate Transcranial MRgFUS (DEVICE).
Who is sponsoring clinical trial NCT01772693?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01772693's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia